ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
Dow Jones
39.118,86
-0,12%
Euro vs US Dollar
1,07205
0,00%
Bitcoin
60.726,82
-0,27%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. NanoViricides Inc (NNVC)

  7. NanoViricides Inc (NNVC) News

NNVC

NanoViricides (NNVC)

NanoViricides Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:NNVC
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202416h07InvestorsHub NewsWireNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonAMEX:NNVCNanoViricides Inc
16/02/202422h53Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
14/02/202422h55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NNVCNanoViricides Inc
19/01/202422h44Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
04/12/202322h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NNVCNanoViricides Inc
13/10/202322h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:NNVCNanoViricides Inc
28/09/202322h44Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:NNVCNanoViricides Inc
01/09/202322h46Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
06/07/202317h16InvestorsHub NewsWireClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical NeedsAMEX:NNVCNanoViricides Inc
25/05/202322h34Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
08/05/202323h20Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:NNVCNanoViricides Inc
04/05/202312h45GlobeNewswire Inc.NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityAMEX:NNVCNanoViricides Inc
14/02/202323h24Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
13/02/202323h02Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
23/12/202212h04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:NNVCNanoViricides Inc
15/11/202222h32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
04/11/202221h33Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:NNVCNanoViricides Inc
13/10/202223h13Edgar (US Regulatory)Annual Report (10-k)AMEX:NNVCNanoViricides Inc
29/09/202218h20Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
11/08/202200h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NNVCNanoViricides Inc
16/05/202222h55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
15/11/202122h55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
15/11/202113h09InvestorsHub NewsWireNanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2AMEX:NNVCNanoViricides Inc
12/10/202112h16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
11/10/202112h49InvestorsHub NewsWireNanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus ActivityAMEX:NNVCNanoViricides Inc
05/10/202112h45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
05/10/202112h45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
28/09/202122h32Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
22/09/202112h48InvestorsHub NewsWireSignificantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
22/09/202112h45PR Newswire (US)Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
 Showing the most relevant articles for your search:AMEX:NNVC

Kürzlich von Ihnen besucht

NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
COIN
SOLUSD
Solana
AMEX
SPY
SPDR S&P 500
CCOM
SILVER
SILVER
TG
NOV
Novo Nordisk
NASDAQ
TSLA
Tesla
TG
D7G
Nel ASA
PM
XAUUSD
Gold vs US Dollar
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
USOTC
DTEGY
Deutsche Telekom (QX)
TG
ALV
Allianz
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten